Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimal features of a new beta-blocker.

J L Reid1

  • 1University of Glasgow, Stobhill General Hospital, United Kingdom.

American Heart Journal
|November 1, 1988
PubMed
Summary

Selecting beta-blockers requires balancing risks and benefits. Newer agents offer improved properties, but careful patient assessment remains key for optimal outcomes and quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood pressure in genetically hypertensive rats. Influence of the Y chromosome.

Hypertension (Dallas, Tex. : 1979)·1995
Same author

Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.

Arteriosclerosis, thrombosis, and vascular biology·1995
Same author

Pharmacokinetic and pharmacodynamic aspects of the choice of components of combination therapy.

Journal of human hypertension·1995
Same author

Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.

Annals of the New York Academy of Sciences·1995
Same author

Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II.

Journal of human hypertension·1995
Same author

Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.

Journal of cardiovascular pharmacology·1995

Area of Science:

  • Pharmacology
  • Cardiology
  • Drug Therapeutics

Background:

  • Beta-blockers are crucial therapeutics, necessitating careful patient selection due to their risk-benefit profile.
  • Despite decades of use, challenges persist in optimizing beta-blocker therapy.
  • Understanding drug properties is vital for managing adverse effects and patient needs.

Purpose of the Study:

  • To review the challenges and considerations in selecting and using beta-blockers.
  • To highlight the importance of drug properties beyond simple selectivity.
  • To emphasize patient-centered criteria in therapeutic decisions.

Main Methods:

  • Review of existing literature on beta-blocker pharmacology and clinical use.
  • Analysis of pharmacokinetic and pharmacodynamic properties of different beta-blocker classes.
  • Discussion of adverse effects and patient-specific factors influencing drug choice.

Main Results:

  • Beta1-cardioselectivity is beneficial, but partial agonist activity may be more critical for mitigating withdrawal effects.
  • Lipophilic beta-blockers can cause central nervous system adverse effects, requiring dose titration.
  • Hydrophilic agents present challenges with gastrointestinal absorption and renal impairment considerations.

Conclusions:

  • Optimal beta-blocker selection depends on a balance of clinical assessment, quality of life, and patient preference.
  • No ideal beta-adrenoceptor blocking agent exists, but newer drugs possess valuable clinical attributes.
  • Individualized therapy and careful monitoring are essential for effective beta-blocker treatment.

Related Experiment Videos